Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reissue Patent
2011-07-19
2011-07-19
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S096000, C544S097000, C544S044000, C544S059000, C546S243000, C514S227200, C514S227500, C514S227800, C514S315000, C514S317000
Reissue Patent
active
RE042562
ABSTRACT:
This invention relates to potent selective agonists of the EP4subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.
REFERENCES:
patent: 4177346 (1979-12-01), Nelson et al.
patent: 4299970 (1981-11-01), Cassidy et al.
patent: 4690931 (1987-09-01), Wick et al.
patent: 4960771 (1990-10-01), Rajadhyaksha
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 6043275 (2000-03-01), Maruyama et al.
patent: 6344477 (2002-02-01), Sharif
patent: 6747037 (2004-06-01), Old et al.
patent: 2002/0065308 (2002-05-01), Cameron et al.
patent: 0 008 186 (1979-07-01), None
patent: 0855389 (1998-01-01), None
patent: 1114816 (2001-07-01), None
patent: 1 524 818 (1974-11-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 00/21542 (2000-04-01), None
patent: WO 01/46140 (2001-06-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 02/24647 (2002-03-01), None
patent: WO 02/42268 (2002-05-01), None
patent: WO 02/060863 (2002-08-01), None
patent: WO 01/72268 (2002-10-01), None
patent: WO 02/077168 (2002-10-01), None
patent: WO 03/047417 (2003-06-01), None
patent: WO 03/047513 (2003-06-01), None
patent: WO 03/105724 (2003-12-01), None
patent: WO 03/105847 (2003-12-01), None
patent: WO 03/105868 (2003-12-01), None
patent: WO 2004/063158 (2004-07-01), None
U. Schlotzer-Schrehardt et al., “Expression and Localization of FP and EP Prostanoid Receptor Subtypes in Human Ocular Tissues”, 2002, pp. 1475-1487, vol. 43, No. 5, Investigative Ophthalmology & Visual Science.
P. Barraclough et al., “Heterocyclic Prostaglanding Analoughes. Part 4, Piperazine-2,5-diones, Pyrazolidine-3,5-diones, 1,2,4-Triazolidinediones, 1,3,4-Oxadiiazolidine-diones and 1,3,4-Thiadiazolidinediones”, 1980, pp. 2096-2105, J.C.S. Perkin I.
R. A. Schumer et al., “The Nerve of Glaucoma”, 1994, pp. 37-44, vol. 112, Arch Ophthalmol.
M. Weinreb et al., “Different Pattern of Alkaline Phosphatase, Osteopontin, and Osteocalcin Expression in Developing Rate Bone Visualized by in Situ Hybridization”, 1990, vol. 5, No. 8, J. of Bone and Mineral Research.
D. A. Dartt et al., “Localization of Nerves Adjacent to Goblet Cells in Rat Conjunctiva” 1994, pp. 993-1000, vol. 14, Curr. Eye Res.
L. Dandona et al., “Selective Effects of Experimental Glaucoma on Axonal Transport by Retinal Ganglion Cells to the Dorsal Lateral Geniculate Nucleus”, 1991, pp. 1593-1599, vol. 32, No. 5, Investigative Ophthalmology & Visual Sciences.
I. K. Gipson et al., “Mucin Genes Expressed by the Ocular Surface Epithelium”, 1997, pp. 81-98, vol. 16, No. 1, Progress in Retinal and Eye Research.
D. M. Shinar et al., “Expression of alpha V and Beta3Integrin Subunits in Rat Osteoclasts in Situ”, 1993, pp. 403-414, vol. 8, No. 4, J. of Bone and Mineral Research.
M. A. Lemp et al., “Report of the National Eye Instittue/Industry Workshop on Clinical Trials in Dry Eyes”, 1995, pp. 221-232, vol. 21, No. 4, CLAO Journal.
M. Abramovitz et al., “The Utilization of Recombinant Prostanoid Receptors to Determine the Affinities and Selectivities of Prostaglandins and Related Analogs”, 2000, pp. 285-293, vol. 1483, Biochimica et Biophysica Acta.
P. Chomczynski et al., “Single-Step Mehtod of RNA Isolation by Acid Guanidinium Thiocyanante-Phenol-Chloroform Extraction”, 1987, pp. 156-159, vol. 162, Analytical Biochemistry.
S.B. Rodan et al., “Growth Stimulation of Rat Calvaria Osteoblastic Cells by Acidic Fibroblast Growth Factor”, 1987, pp. 1917-1923, vol. 121, No. 6, Endocrinology.
M. Abramovitz et al., “Human Prostanoid Receptors: Cloning and Characterization”, 1995, pp. 499-504, vol. 23, Advances in Prostaglandin Thromboxane, and Leukotriene Research.
J. E. Larco et al., “Epithelioid and Fibroblastic Rat Kidney Cell Clones: Epidermal Growth Factor (EGF) Receptors and the Effect of Mouse Sarcoma Virus Transformation”, 1978, pp. 335-342, vol. 94, J. Cell Physiol.
E. M. Ross. “Mechanisms of Drug Action and the Realtionship Between Drug Concentration and Effect”, pp. 29-41, chapter 2, Goodman and Gilman's Pharmacological Basis of Therapetics.
T.J. Hodgkinson et al., “Practical Asymmetric Synthesis of Both Enatiomers of 6-(Hydroxymethyl) piperidin-2-one”, pp. 1141-1144. Synthesis (1998).
Billot Xavier
Colucci John
Han Yongxin
Wilson Marie-Claire
Young Robert N.
Ayler Sulvia A.
Devlin Gerard M.
Habte Kahsay T
Merck Frosst Canada
LandOfFree
EP 4 receptor agonist, compositions and methods thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with EP 4 receptor agonist, compositions and methods thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and EP 4 receptor agonist, compositions and methods thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2718308